SCHEDULE: CVI Investments Reports 4.9% Stake in Reviva Pharma

CVI Investments, managed by Heights Capital Management, Inc., has reported a 4.9% passive beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. through warrants.

Summary

• CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., collectively reported beneficial ownership of 3,571,603 shares of Reviva Pharmaceuticals Holdings, Inc. common stock.
• This ownership represents 4.9% of the company's outstanding common stock.
• The reported shares are issuable upon the exercise of warrants.
• The warrants include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 4.99% of the outstanding shares.
• As of the completion of an offering referenced in a Prospectus Supplement filed on June 26, 2025, Reviva Pharmaceuticals Holdings, Inc. had 68,003,613 shares outstanding.

Sentiment

Score: 5

Explanation: The filing is a routine passive ownership disclosure (Schedule 13G) and does not contain information that would significantly alter the sentiment towards the company, indicating a neutral impact.

Positives

• An institutional investor, CVI Investments, Inc., holds a significant stake in Reviva Pharmaceuticals, indicating potential confidence.
• The stake is held through warrants, suggesting a long-term investment perspective.

Negatives

• No specific negative information is disclosed in this passive ownership filing.

Risks

• The exercise of warrants is limited to prevent beneficial ownership from exceeding 4.99% of the outstanding shares, which could cap the investor's immediate influence or upside from warrant exercise.

Future Outlook

The filing is a passive ownership disclosure and does not contain forward-looking statements or guidance from Reviva Pharmaceuticals Holdings, Inc. regarding its operations or financial performance.

Management Comments

• No direct management comments from Reviva Pharmaceuticals Holdings, Inc. are included in this passive ownership filing.

Industry Context

This filing indicates a significant passive investment by CVI Investments, Inc. in Reviva Pharmaceuticals Holdings, Inc., a company operating in the biotechnology and pharmaceutical sector. Such investments are common for institutional funds seeking exposure to specific industry growth opportunities.

Comparison to Industry Standards

• This Schedule 13G filing is a standard disclosure of beneficial ownership and does not provide specific operational or financial data points for direct comparison to industry-specific benchmarks or competitor performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed positively as a vote of confidence.
• Employees, customers, suppliers, creditors: No direct impact from this passive ownership disclosure.

Next Steps

• No specific future actions, events, or milestones are mentioned in this passive ownership filing by either the company or the reporting persons.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of passive beneficial ownership and does not contain new operational, financial, or strategic information about Reviva Pharmaceuticals Holdings, Inc. that would warrant a change in investment thesis. The presence of an institutional investor holding a significant stake through warrants is noted, but without further company-specific updates, a 'hold' recommendation is appropriate.

Keywords

Reviva Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Biotechnology, Pharmaceuticals, Investment